Arrowhead (ARWR) FQ1 2026 Revenue Hits $264M as REDEMPLO Approval Marks Commercial Shift
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) is one of the best multibagger stocks to invest in according to billionaires.
Arrowhead Pharmaceuticals Inc. (ARWR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | VenBio Select Advisor Kurt Von Emster | 10,625,000 | $705,393,750 | -3% | 6.93% |
| 2. | Slate Path Capital David Greenspan | 2,523,500 | $167,535,165 | -50% | 2.26% |
| 3. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,175,645 | $144,441,072 | +31% | 0.85% |
| 4. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 2,087,953 | $138,619,200 | +1% | 0.08% |
| 5. | Deerfield Management James E. Flynn | 1,832,946 | $121,689,285 | +85% | 1.55% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $22.00 | 500 | $11,000.00 | 36,080 | 2024-04-18 | Filing | |
| $25.00 | 500 | $12,500.00 | 35,580 | 2024-04-10 | Filing | |
| $27.34 | 150 | $4,101.00 | 35,080 | 2024-04-02 | Filing | |
| $27.50 | 850 | $23,375.00 | 34,930 | 2024-03-26 | Filing | |
| $28.00 | 400 | $11,200.00 | 34,080 | 2024-03-22 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $64.19 | 10,000 | $641,900.00 | 236,958 | 2026-03-05 | Filing | |
| $68.00 | 46 | $3,128.00 | 474,908 | 2026-01-05 | Filing | |
| $64.04 | 2,336 | $149,597.44 | 474,954 | 2026-01-05 | Filing | |
| $62.91 | 5,873 | $369,470.43 | 477,290 | 2026-01-05 | Filing | |
| $62.25 | 900 | $56,025.00 | 483,163 | 2026-01-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 21,318,582 | $1,415,340,659 | 0.02% | |
| 2. | 15,293,121 | $1,015,310,304 | 0.01% | |
| 3. | 6,520,408 | $432,889,919 | 0.02% | |
| 4. | 6,403,830 | $425,150,274 | 0.01% | |
| 5. | 3,264,963 | $216,798,525 | 0.01% |
News See All
12 Best Multibagger Stocks to Invest In According to Billionaires
On March 11, Tom Lee of Fundstrat joined 'Closing Bell' on CNBC to discuss his market outlook amid rising oil prices and sector volatility.
Morgan Stanley Notes 2026 Sales From Arrowhead Pharmaceuticals, Inc. (ARWR)'s Familial Chylomicronemia Syndrome Likely Limited
TheFly reported on February 6 that Morgan Stanley lowered its price target for ARWR to $78 from $81 and kept an Equal Weight rating.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q1 2026 Earnings Call Transcript February 5, 2026Arrowhead Pharmaceuticals, Inc. misses on earnings expectations.
Piper Sandler Highlights Arrowhead Pharmaceuticals, Inc. (ARWR) Pipeline With Upcoming Phase III Hypertriglyceridemia Data
TheFly reported on January 13 that Piper Sandler lifted its price target on ARWR to $110 from $100, and reiterated an Overweight rating.
Arrowhead Pharmaceuticals, Inc. (ARWR): A Bull Case Theory
We came across a bullish thesis on Arrowhead Pharmaceuticals, Inc. on BioEquity Watch’s Substack. In this article, we will summarize the bulls’ thesis on ARWR.
Piper Sandler Maintains an Overweight rating on Arrowhead Pharmaceuticals, Inc. (ARWR)
On December 17, 2025, TheFly reported that Piper Sandler maintained its Overweight rating for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and lifted its price objective from $70 to $100.
Arrowhead (ARWR) Hits 3-Year High on Strong Earnings, FDA Approval
Arrowhead Pharmaceuticals soared to a new three-year high on Wednesday, as investors took heart from its impressive earnings performance for the full fiscal year, alongside the Food and Drug Administration...
Hedge Fund Resource Center